Last reviewed · How we verify

Nicotine replacement

Instituto Fernandes Figueira · FDA-approved active Small molecule

Nicotine binds to nicotinic acetylcholine receptors in the central and peripheral nervous system to reduce cravings and withdrawal symptoms during smoking cessation.

Nicotine binds to nicotinic acetylcholine receptors in the central and peripheral nervous system to reduce cravings and withdrawal symptoms during smoking cessation. Used for Smoking cessation as an aid to quit smoking.

At a glance

Generic nameNicotine replacement
Also known asNicotine Replacement Therapy, NRT, nicotine replacement therapy, nicotine replacement therapy, Nicotine Replacement Therapy, NRT, Nicoderm, Nicorrette
SponsorInstituto Fernandes Figueira
Drug classNicotinic acetylcholine receptor agonist
TargetNicotinic acetylcholine receptors
ModalitySmall molecule
Therapeutic areaSmoking Cessation / Addiction Medicine
PhaseFDA-approved

Mechanism of action

Nicotine replacement therapy (NRT) delivers nicotine through non-combustible routes (patches, gum, lozenges, nasal spray, or inhalers) to satisfy nicotine dependence while avoiding the harmful effects of tobacco smoke. By activating nicotinic acetylcholine receptors, it alleviates withdrawal symptoms such as irritability, anxiety, and difficulty concentrating, thereby supporting abstinence from smoking.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: